BRIM Biotechnology Company Description

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan.

The company’s lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease.

It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that has completed Phase 2 clinical trial to treat wet age-related macular degeneration; and BRM521, a PEDF-derived short peptide that is in pre-clinical trial to relieve and repair tissue damage caused by osteoarthritis.

BRIM Biotechnology, Inc. was founded in 2013 and is based in Taipei, Taiwan.